1
|
Morice P, Leary A, Creutzberg C,
Abu-Rustum N and Darai E: Endometrial cancer. Lancet.
387:1094–1108. 2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Duong LM, Wilson RJ, Ajani UA, Singh SD
and Eheman CR: Trends in endometrial cancer incidence rates in the
United States, 1999–2006. J Womens Health (Larchmt). 20:1157–1163.
2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Donkers H, Bekkers R, Massuger L and
Galaal K: Systematic review on socioeconomic deprivation and
survival in endometrial cancer. Cancer Causes Control.
30:1013–1022. 2019. View Article : Google Scholar : PubMed/NCBI
|
4
|
Sanni OB, Mc Menamin ÚC, Cardwell CR,
Sharp L, Murray LJ and Coleman HG: Commonly used medications and
endometrial cancer survival: A population-based cohort study. Br J
Cancer. 117:432–438. 2017. View Article : Google Scholar : PubMed/NCBI
|
5
|
Morrison J: Endometrial cancer follow up;
finding the confidence to let go? BJOG. 125:17152018. View Article : Google Scholar : PubMed/NCBI
|
6
|
Makker V, Green AK, Wenham RM, Mutch D,
Davidson B and Miller DS: New therapies for advanced, recurrent,
and metastatic endometrial cancers. Gynecol Oncol Res Pract.
4:192017. View Article : Google Scholar : PubMed/NCBI
|
7
|
Busch EL, Crous-Bou M, Prescott J, Chen
MM, Downing MJ, Rosner BA, Mutter GL and De Vivo I: Endometrial
cancer risk factors, hormone receptors, and mortality prediction.
Cancer Epidemiol Biomarkers Prev. 26:727–735. 2017. View Article : Google Scholar : PubMed/NCBI
|
8
|
Mitamura T, Dong P, Ihira K, Kudo M and
Watari H: Molecular-targeted therapies and precision medicine for
endometrial cancer. Jpn J Clin Oncol. 49:108–120. 2019. View Article : Google Scholar : PubMed/NCBI
|
9
|
Remmerie M and Janssens V: PP2A: A
promising biomarker and therapeutic target in endometrial cancer.
Front Oncol. 9:4622019. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kunitomi H, Kobayashi Y, Wu RC, Takeda T,
Tominaga E, Banno K and Aoki D: LAMC1 is a prognostic factor and a
potential therapeutic target in endometrial cancer. J Gynecol
Oncol. 31:e112020. View Article : Google Scholar : PubMed/NCBI
|
11
|
Shang Q, Yang Z, Jia R and Ge S: The novel
roles of circRNAs in human cancer. Mol Cancer. 18:62019. View Article : Google Scholar : PubMed/NCBI
|
12
|
Yu T, Wang Y, Fan Y, Fang N, Wang T, Xu T
and Shu Y: CircRNAs in cancer metabolism: A review. J Hematol
Oncol. 12:902019. View Article : Google Scholar : PubMed/NCBI
|
13
|
Fan Z, Bai Y, Zhang Q and Qian P: CircRNA
circ_POLA2 promotes lung cancer cell stemness via regulating the
miR-326/GNB1 axis. Environ Toxicol. 35:1146–1156. 2020. View Article : Google Scholar : PubMed/NCBI
|
14
|
Cao Y, Li J, Jia Y, Zhang R and Shi H:
CircRNA circ_POLA2 promotes cervical squamous cell carcinoma
progression via regulating miR-326/GNB1. Front Oncol. 10:9592020.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Zhang Y, Guo J, Li D, Xiao B, Miao Y,
Jiang Z and Zhuo H: Down-regulation of miR-31 expression in gastric
cancer tissues and its clinical significance. Med Oncol.
27:685–689. 2010. View Article : Google Scholar : PubMed/NCBI
|
16
|
Raffone A, Travaglino A, Mascolo M,
Carotenuto C, Guida M, Mollo A, Insabato L and Zullo F:
Histopathological characterization of ProMisE molecular groups of
endometrial cancer. Gynecol Oncol. 157:252–259. 2020. View Article : Google Scholar : PubMed/NCBI
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Takeuchi M, Matsuzaki K and Harada M:
Evaluating myometrial invasion in endometrial cancer: Comparison of
reduced field-of-view diffusion-weighted imaging and dynamic
contrast-enhanced MR imaging. Magn Reson Med Sci. 17:28–34. 2018.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Zheng W, Liu Z, Zhang W and Hu X: MiR-31
functions as an oncogene in cervical cancer. Arch Gynecol Obstet.
292:1083–1089. 2015. View Article : Google Scholar : PubMed/NCBI
|
20
|
Mitamura T, Watari H, Wang L, Kanno H,
Kitagawa M, Hassan MK, Kimura T, Tanino M, Nishihara H, Tanaka S
and Sakuragi N: MicroRNA 31 functions as an endometrial cancer
oncogene by suppressing Hippo tumor suppressor pathway. Mol Cancer.
13:972014. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ye F, Tang QL, Ma F, Cai L, Chen M, Ran
XX, Wang XY and Jiang XF: Analysis of the circular RNA
transcriptome in the grade 3 endometrial cancer. Cancer Manag Res.
11:6215–6227. 2019. View Article : Google Scholar : PubMed/NCBI
|